J. Barbet, M. Bardiès, and M. Bourgeois, Radiolabeled Antibodies for Cancer Imaging and Therapy, Methods Mol Biol, vol.907, pp.681-697978, 2012.
DOI : 10.1007/978-1-61779-974-7_38

J. Pouget, I. Navarro-teulon, and M. Bardiès, Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-734, 2011.
DOI : 10.1038/nrclinonc.2011.160

J. Gorin, J. Ménager, and S. Gouard, Antitumor Immunity Induced after ?? Irradiation, Neoplasia, vol.16, issue.4, pp.319-328, 2014.
DOI : 10.1016/j.neo.2014.04.002

S. Larson, J. Carrasquillo, and N. Cheung, Radioimmunotherapy of human tumours, Nature Reviews Cancer, vol.9, issue.6, pp.347-360, 2015.
DOI : 10.4161/cbt.6.6.4089

F. Kraeber-bodéré, C. Bodet-milin, and C. Rousseau, Radioimmunoconjugates for the Treatment of Cancer, Seminars in Oncology, vol.41, issue.5, pp.613-622, 2014.
DOI : 10.1053/j.seminoncol.2014.07.004

C. Bodet-milin, L. Ferrer, and A. Pallardy, Radioimmunotherapy of B-cell non-Hodgkin???s lymphoma, Frontiers in Oncology, vol.3, p.177, 2013.
DOI : 10.3389/fonc.2013.00177

T. Witzig, A. Molina, and L. Gordon, Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan, Cancer, vol.23, issue.9, pp.1804-1810, 2007.
DOI : 10.1002/cncr.22617

F. Morschhauser, J. Radford, and A. Van-hoof, Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008.
DOI : 10.1200/JCO.2008.17.2015

T. Illidge, S. Mayes, and R. Pettengell, Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria, Journal of Clinical Oncology, vol.32, issue.3, pp.212-218, 2014.
DOI : 10.1200/JCO.2013.50.3110

R. Fisher, M. Kaminski, and R. Wahl, Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin???s Lymphomas, Journal of Clinical Oncology, vol.23, issue.30, pp.7565-7573, 2005.
DOI : 10.1200/JCO.2004.00.9217

F. Morschhauser, F. Kraeber-bodéré, and W. Wegener, High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.28, issue.23, pp.3709-3716, 2010.
DOI : 10.1200/JCO.2009.27.7863

T. Illidge, Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, Journal of Clinical Oncology, vol.28, issue.18, pp.2944-2946, 2010.
DOI : 10.1200/JCO.2009.26.8748

C. Rousseau, L. Ferrer, and S. Supiot, Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumor Biology, vol.32, issue.5, pp.679-688, 2012.
DOI : 10.1007/s13277-012-0362-y

M. Chérel, S. Gouard, and J. Gaschet, 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.213-1597, 2013.
DOI : 10.2967/jnumed.112.111997

S. Gouard, A. Pallardy, and J. Gaschet, Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy, Nuclear Medicine and Biology, vol.41, pp.30-35008, 2014.
DOI : 10.1016/j.nucmedbio.2014.02.008

J. Jurcic, S. Larson, and G. Sgouros, Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, issue.4, pp.1233-1239, 2002.
DOI : 10.14694/EdBook_AM.2014.34.e126

J. Barbet, M. Chérel, and J. Chatal, Alpha particles more promising than toxins?, European Journal of Nuclear Medicine and Molecular Imaging, vol.15, issue.12, pp.849-850, 2010.
DOI : 10.1007/s00259-010-1421-5

URL : http://doi.org/10.1007/s00259-010-1421-5

J. Chatal, F. Davodeau, and M. Cherel, Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, pp.36-40, 2009.
DOI : 10.4103/0973-1482.55139

G. Sgouros, J. Roeske, and M. Mcdevitt, Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy, MIRD Pamphlet No. J Nucl Med, vol.2251, issue.2, pp.311-328, 2010.

H. Döhner, E. Estey, and S. Amadori, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2009.
DOI : 10.1182/blood-2009-07-235358

C. Pui, L. Robison, and A. Look, Acute lymphoblastic leukaemia, The Lancet, vol.371, issue.9617, pp.1030-1043, 2008.
DOI : 10.1016/S0140-6736(08)60457-2

M. Béné, T. Nebe, and P. Bettelheim, Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10, Leukemia, vol.75, issue.4, pp.567-574312, 2010.
DOI : 10.1080/15476910802129661

K. Beldjord, S. Chevret, and V. Asnafi, Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia, Blood, vol.123, issue.24, pp.3739-3749, 2014.
DOI : 10.1182/blood-2014-01-547695

P. Chevallier, N. Robillard, and G. Houille, Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases, Leukemia, vol.89, issue.4, pp.806-807303, 2008.
DOI : 10.1002/cncr.23824

P. Chevallier, F. Huguet, and E. Raffoux, Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study, Haematologica, vol.100, issue.4, pp.128-131, 2015.
DOI : 10.3324/haematol.2014.120220

D. Scheinberg, D. Lovett, and C. Divgi, A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide., Journal of Clinical Oncology, vol.9, issue.3, pp.478-490, 1991.
DOI : 10.1200/JCO.1991.9.3.478

M. Schwartz, D. Lovett, and A. Redner, Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias., Journal of Clinical Oncology, vol.11, issue.2, pp.294-303, 1993.
DOI : 10.1200/JCO.1993.11.2.294

J. Jurcic, P. Caron, and T. Nikula, Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias, Cancer Res, vol.55, issue.23, pp.5908-5910, 1995.

M. Mcdevitt, R. Finn, and D. Ma, Preparation of alpha-emitting 213Bi- labeled antibody constructs for clinical use, J Nucl Med, vol.40, issue.10, pp.1722-1727, 1999.

T. Nikula, M. Mcdevitt, and R. Finn, Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti- CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry, J Nucl Med, vol.40, issue.1, pp.166-176, 1999.

G. Sgouros, A. Ballangrud, and J. Jurcic, Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia, J Nucl Med, vol.40, issue.11, pp.1935-1946, 1999.

T. Rosenblat, M. Mcdevitt, and D. Mulford, Sequential Cytarabine and ??-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia, Clinical Cancer Research, vol.16, issue.21, pp.5303-5311, 2010.
DOI : 10.1158/1078-0432.CCR-10-0382

M. Mcdevitt, D. Ma, and L. Lai, Tumor Therapy with Targeted Atomic Nanogenerators, Science, vol.294, issue.5546, pp.1537-1540, 2001.
DOI : 10.1126/science.1064126

J. Jurcic, T. Rosenblat, and M. Mcdevitt, Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.768, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.6516

J. Jurcic and T. Rosenblat, Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, pp.126-131
DOI : 10.14694/EdBook_AM.2014.34.e126

M. Omary, I. Trowbridge, and H. Battifora, Human homologue of murine T200 glycoprotein, Journal of Experimental Medicine, vol.152, issue.4, pp.842-852, 1980.
DOI : 10.1084/jem.152.4.842

O. Press, A. Farr, and K. Borroz, Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies, Cancer Res, vol.49, issue.17, pp.4906-4912, 1989.

R. Van-der-jagt, C. Badger, and F. Appelbaum, Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model, Cancer Res, vol.52, issue.1, pp.89-94, 1992.

D. Matthews, F. Appelbaum, and J. Eary, Phase I study of (131)I-anti- CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome, Blood, vol.94, issue.4, pp.1237-1247, 1999.

J. Pagel, F. Appelbaum, and J. Eary, 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission, Blood, vol.107, issue.5, pp.2184-2191, 2005.
DOI : 10.1182/blood-2005-06-2317

J. Pagel, T. Gooley, and J. Rajendran, Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome, Blood, vol.114, issue.27, pp.5444-5453, 2009.
DOI : 10.1182/blood-2009-03-213298

D. Matthews, F. Appelbaum, and J. Eary, Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation, Blood, vol.85, issue.4, pp.1122-1131, 1995.

R. Mawad, T. Gooley, and J. Rajendran, Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome, Biology of Blood and Marrow Transplantation, vol.20, issue.9, pp.1363-1368, 2014.
DOI : 10.1016/j.bbmt.2014.05.014

J. Orozco, E. Balkin, and T. Gooley, Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model, PLoS ONE, vol.136, issue.12, 2014.
DOI : 10.1371/journal.pone.0113601.t001

J. Orozco, T. Bäck, and A. Kenoyer, Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, issue.18, pp.3759-3767, 2013.
DOI : 10.1182/blood-2012-11-467035

J. Pagel, N. Hedin, and L. Drouet, Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy, Blood, vol.111, issue.4, pp.2261-2268, 2008.
DOI : 10.1182/blood-2007-06-097451

D. Goldenberg, R. Sharkey, and G. Paganelli, Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006.
DOI : 10.1200/JCO.2005.03.8471

D. Green, J. Pagel, and E. Nemecek, Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates, Blood, vol.114, issue.6, pp.1226-1235, 2009.
DOI : 10.1182/blood-2009-03-210344

J. Pagel, A. Kenoyer, and T. Bäck, Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model, Blood, vol.118, issue.3, pp.703-711, 2011.
DOI : 10.1182/blood-2011-04-347039

J. Kotzerke, D. Bunjes, and D. Scheinberg, Radioimmunoconjugates in acute leukemia treatment: the future is radiant, Bone Marrow Transplantation, vol.101, issue.12, pp.1021-1026, 2005.
DOI : 10.1038/sj.bmt.1705182

I. Buchmann, T. Kull, and G. Glatting, A comparison of the biodistribution and biokinetics of 99mTc-anti-CD66 mAb BW 250/183 and 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.5, pp.667-673, 2003.
DOI : 10.1007/s00259-002-1106-9

M. Ringhoffer, N. Blumstein, and B. Neumaier, 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study, British Journal of Haematology, vol.37, issue.4, pp.604-613, 2005.
DOI : 10.1182/blood-2003-03-0855

A. Schulz, G. Glatting, and M. Hoenig, Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases, Blood, vol.117, issue.17, pp.4642-4650, 2011.
DOI : 10.1182/blood-2010-06-284349

C. Koenecke, M. Hofmann, and O. Bolte, Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia, International Journal of Hematology, vol.92, issue.4, pp.414-421, 2008.
DOI : 10.1007/s12185-008-0043-1

E. Röttinger, D. Bartkowiak, and D. Bunjes, Erh??hte Nephrotoxizit??t bei Ganzk??rperbestrahlung und zus??tzlicher Radioimmuntherapie, Strahlentherapie und Onkologie, vol.179, issue.10, pp.702-707, 2003.
DOI : 10.1007/s00066-003-1090-4

T. Zenz, R. Schlenk, and G. Glatting, Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation, J Nucl Med, vol.47, issue.2, pp.278-286, 2006.

D. Bunjes, I. Buchmann, and C. Duncker, Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study, Blood, vol.98, issue.3, pp.565-572, 2001.
DOI : 10.1182/blood.V98.3.565

A. Lauter, A. Strumpf, and U. Platzbecker, T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation, British Journal of Haematology, vol.45, issue.Suppl, pp.910-917, 2010.
DOI : 10.1111/j.1365-2141.2009.08025.x

S. Schneider, A. Strumpf, and J. Schetelig, Reduced-intensity conditioning combined with (188)Rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: The role of in vivo t cell depletion, Biol Blood Marrow Transplant, 2015.

P. Kletting, C. Maaß, and S. Reske, Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy, PLOS ONE, vol.6, issue.2
DOI : 10.1371/journal.pone.0127934.s004

D. Putzer, G. Dobrozemsky, and R. Haubner, 124I-Anti-CD52 Dosimetry Before Radioimmunotherapy as Part of Conditioning for Stem Cell Transplantation in Acute Leukemia, Clinical Nuclear Medicine, vol.37, issue.4, pp.390-392, 2012.
DOI : 10.1097/RLU.0b013e3182443b64

P. Chevallier, C. Bodet-milin, and N. Robillard, B-ALL: proof of principle, European Journal of Haematology, vol.9, issue.6, pp.552-556, 2013.
DOI : 10.1111/ejh.12183

P. Chevallier, E. T. Robillard, and N. , 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study, The Lancet Haematology, vol.2, issue.3, pp.108-117, 2015.
DOI : 10.1016/S2352-3026(15)00020-4

E. Raetz, M. Cairo, and M. Borowitz, Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study, Journal of Clinical Oncology, vol.26, issue.22, pp.3756-3762, 2008.
DOI : 10.1200/JCO.2007.15.3528

A. Advani, S. Mcdonough, and S. Coutre, SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia, British Journal of Haematology, vol.120, issue.4, pp.504-509, 2014.
DOI : 10.1111/bjh.12778

J. Carnahan, R. Stein, and Z. Qu, Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab, Molecular Immunology, vol.44, issue.6, pp.1331-1341, 2007.
DOI : 10.1016/j.molimm.2006.05.007

F. Kraeber-bodere, A. Pallardy, L. Gouill, and S. , Consolidation Anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: A LYSA Phase II prospective trial